WHY WE DO IT
Glioblastoma (GBM) is one of the most complex, deadly, and treatment-resistant cancers. Survival rates and mortality statistics for GBM have been virtually unchanged for decades.
WHAT WE DO
Alpheus Medical is developing an innovative solution to treat aggressive brain tumors using ultrasound delivered via a non-invasive, proprietary device.
The device uses sonodynamic therapy (SDT), a treatment that uses ultrasound to activate a drug targeting cancer cells. Alpheus Medical’s proprietary device is applied to the entire diseased hemisphere, targeting tumor cells you can see and those you can’t.
Glioblastoma is a diffuse, infiltrative disease with tumor cells invading far beyond the borders of the visible tumor. Even with a complete resection, we know that only part of the tumor has been addressed. This is a disease that requires more than just a focal therapy.
Alpheus Medical is developing a technology to address this problem by targeting tumor cells beyond the borders of the tumor via a non-invasive procedure. During the procedure, the patient is awake and is able to go home the same day. No imaging, such as MRI, is required during the treatment.
This investigational treatment represents a paradigm shift in the way patients with brain tumors are treated.
HOW WE DO IT
The patient drinks a drug that is already FDA approved for use in brain tumor surgery
Once the tumor cells are loaded with drug molecules, ultrasound is non-invasively delivered to the brain by a novel device
When the ultrasound hits the drug molecules they release a form of oxygen (called an oxygen radical) in the cancerous cells, causing cell death
HELP US COMBAT GBM
Researching a NEW & NOVEL option for patients
ABOUT ALPHEUS MEDICAL
Alpheus Medical, Inc, is a privately held company based in Oakdale, Minnesota, developing a novel sonodynamic therapy platform targeting solid body cancers. The company’s lead product utilizes a novel, non-invasive drug device combination for outpatient treatment of recurrent glioblastoma multiforme (rGBM). Alpheus Medical’s work has been developed in conjunction with some of the most accomplished names worldwide in neuro-oncology, and with support from BrightEdge, the impact investment and venture capital arm of the American Cancer Society, and National Brain Tumor Society.